Metformin: A Candidate Drug for Renal Diseases
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Over the past decades metformin has been the optimal first-line treatment for type 2 diabetes mellitus (T2DM). Only in the last few years, it has become increasingly clear that metformin exerts benign pleiotropic actions beyond its prescribed use and ongoing investigations focus on a putative beneficial impact of metformin on the kidney. Both acute kidney injury (AKI) and chronic kidney disease (CKD), two major renal health issues, often result in the need for renal replacement therapy (dialysis or transplantation) with a high socio-economic impact for the patients. Unfortunately, to date, effective treatment directly targeting the kidney is lacking. Metformin has been shown to exert beneficial effects on the kidney in various clinical trials and experimental studies performed in divergent rodent models representing different types of renal diseases going from AKI to CKD. Despite growing evidence on metformin as a candidate drug for renal diseases, in-depth research is imperative to unravel the molecular signaling pathways responsible for metformin’s renoprotective actions. This review will discuss the current state-of-the-art literature on clinical and preclinical data, and put forward potential cellular mechanisms and molecular pathways by which metformin ameliorates AKI/CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Chronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383
Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32064-5 · Cited by 3,842
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 3×
“Indeed, metformin acts on mitochondria by inhibiting complex 1 of the respiratory chain, which leads to a reduction in cellular energy charge [22,77].”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“Subsequently, cytoplasmic ADP/ATP and AMP/ATP ratio’s will increase and activate AMPK, leading to reduction of gluconeogenic gene transcription [4,21,25,26].”
BackgroundWu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · cited 4×
“Multidrug and toxin extrusion 1 (MATE1) and multidrug and toxin extrusion 2 (MATE2) transporters contribute to the renal excretion of metformin, which is eliminated, unchanged, in the urine by glomerular filtration and tubular secretion [1,2].”
BackgroundInfluentialMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 2×
“[29] showed that metformin (50 μM in vitro, single dose 50 mg/kg i.”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 2×
“They found that in mice lacking AMPK in the liver, blood glucose levels were comparable to those in wild-type mice, and that the hypoglycemic effect of metformin was maintained [27].”
BackgroundAMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs
Hardie, D. G., Schaffer, B. E., & Brunet, A. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.013 · Cited by 859 · cited 2×
“Consequently, metformin, as AMPK activator, is able to inhibit the mTOR pathway and cause a delay in renal regeneration and repair [73,76].”
BackgroundMetformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733 · cited 1×
“Further, an important contribution to the antihyperglycemic efficacy of metformin arises from actions within the gut, by increasing glucagon-like peptide 1 (GLP-1) secretion, and possibly altering the gut microbiome [3,4,7,8].”
BackgroundMetformin-associated lactic acidosis: current perspectives on causes and risk
DeFronzo, R., Fleming, G. A., Chen, K., & Bicsak, T. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.014 · Cited by 658 · cited 1×
“Consequently, metabolic degradation of lactic acid by oxidation or gluconeogenesis is reduced and plasma lactate concentration increases [53,54].”
BackgroundMetformin pathways: pharmacokinetics and pharmacodynamics
Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283559b22 · Cited by 495
Metformin Action: Concentrations Matter
He, L., & Wondisford, F. E. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.003 · Cited by 448 · cited 1×
“After oral administration of metformin, a plasma concentration of 10–40 μM is achieved in humans [23,24].”
BackgroundAccumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418 · cited 1×
“After oral administration of metformin, a plasma concentration of 10–40 μM is achieved in humans [23,24].”
BackgroundMetformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase
Hunter, R. W., Hughey, C. C., Lantier, L., Sundelin, E. I., Peggie, M., Zeqiraj, E., Sicheri, F., Jessen, N., Wasserman, D. H., & Sakamoto, K. (2018) · Nature Medicine · doi:10.1038/s41591-018-0159-7 · Cited by 313 · cited 1×
“) inhibited fructose-1-6-bisphosphatase allosterically, by increasing AMP concentration [30].”
BackgroundMetformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290 · cited 1×
“Metformin has shown substantial effectiveness in polycystic ovarian syndrome [11], cancer [12], heart and cardiovascular disorders [13], nonalcoholic fatty liver disease [14], and premature puberty [3,15].”
BackgroundDing, Y., Kim, S. L., Lee, S.-Y., Koo, J. K., Wang, Z., & Choi, M. E. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101068 · Cited by 264
Ekström, N., Schiöler, L., Svensson, A.-M., Eeg-Olofsson, K., Miao Jonasson, J., Zethelius, B., Cederholm, J., Eliasson, B., & Gudbjörnsdottir, S. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001076 · Cited by 221
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211
Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4
Lalau, J.-D., Kajbaf, F., Bennis, Y., Hurtel-Lemaire, A.-S., Belpaire, F., & De Broe, M. E. (2018) · Diabetes Care · doi:10.2337/dc17-2231 · Cited by 162
Cited by
Samuel, S., Varghese, E., Kubatka, P., Triggle, C., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120846 · Cited by 81
Silverii, G. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15749 · Cited by 33
“Despite these limitations to prescription in patients with CKD, metformin has not shown any sign of direct kidney damage; conversely, preclinical data have suggested a possible beneficial effect of metformin on renal disease, 24 in particular on tubular damage.”
Safety and effectiveness of metformin in patients with reduced renal function: a systematic review
Orloff, J., Min, J. Y., Mushlin, A., & Flory, J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14440 · Cited by 24
Metadata
- Authors
- Corremans, R., Vervaet, B. A., D’Haese, P. C., Neven, E., & Verhulst, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-12-21
- Volume
- 20
- Issue
- 1
- Pages
- 42
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2906463760
- Cited by
- 69
- References
- 24
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.